98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383466 | PMC |
http://dx.doi.org/10.1093/ndt/gfac031 | DOI Listing |
Microbiol Res
August 2025
Microbial Processes and Interactions (MiPI), TERRA Teaching and Research Centre, Joint Research Unit 1158 BioEcoAgro, Gembloux Agro-Bio Tech, University of Liège, Gembloux 5030, Belgium. Electronic address:
The biocontrol fungus Purpureocillium lilacinum PLBJ-1 produces leucinostatins, a class of non-ribosomal peptides (NRPs) with broad-spectrum antimicrobial activities. However, the molecular mechanisms underlying the optimization of culture conditions for leucinostatin production remain unexplored. Previous research showed that PLBJ-1 synthesizes leucinostatins more effectively in hand-made Potato Dextrose Broth (PDB-M) than in commercially available PDB (PDB-C).
View Article and Find Full Text PDFComput Biol Med
September 2025
Institute of Biotechnology, Department of Medical Biotechnology, SIMATS Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, 602105, Tamil Nadu, India. Electronic address:
Small humanin-like peptide-6 (SHLP6), is derived from the mitochondrial genome. The 3D structure of SHLP6 was evaluated using PEPstr, with homology modeling predicting a Cyt-C structure with a DOPE score of -645.717 and a GA341 score of 0.
View Article and Find Full Text PDFAquat Toxicol
September 2025
University of Campinas (UNICAMP), Institute of Chemistry, Campinas, São Paulo, Brazil.
Aquatic pollution caused by pesticides raises concerns about the effects on wildlife. While risk assessment protocols with invertebrates focus mainly on arthropods, the effects on gastropods are underexplored. In this way, the impact of exposure to imidacloprid, a neonicotinoid insecticide, and tebuconazole, an azole fungicide, on different life stages of the freshwater snail Physa acuta was investigated.
View Article and Find Full Text PDFInflamm Bowel Dis
September 2025
IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.
Background: The infliximab (IFX) biosimilar, CT-P13, is available as an intravenous (IV) and subcutaneous (SC) formulation. Although current indications allow the transition from IV CT-P13 to SC CT-P13 after two IV administrations, some clinicians prefer to postpone switching until stable clinical remission has been achieved.
Methods: We evaluate the endoscopic response, treatment persistence, clinical remission, endoscopic remission, and safety profile after one year of treatment with IFX in patients switched from IV to SC after 6 weeks (early switch group) or after 6 months (late switch group).
Ther Innov Regul Sci
September 2025
Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Introduction: During the COVID-19 pandemic, regulatory and market access actions were taken to expedite the market entry of COVID-19 medicines. This study aims to (i) capture multi-stakeholder views on these actions, and (ii) provide recommendations for future-proofing routine and health-emergency frameworks.
Methods: Semi-structured interviews were conducted with policy makers/advisors (i.